Clinical Trials on Large-Cell Neuroendocrine Carcinoma

Total 16538 results

National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
Shanghai Chest Hospital

Unknown

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Pulmonary Large Cell Neuroendocrine Carcinoma
Charles Kunos
National Center for Advancing Translational Sciences (NCATS)

Completed

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma (PRECISION-NEC)

Large-Cell Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Lung Non-Small Cell Squamous Carcinoma | Stage IIA Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Lung Atypical Carcinoid Tumor | Minimally Invasive Lung Adenocarcinoma | Lung Neuroendocrine Neoplasm | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Dwight Owen
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Neuroendocrine Tumors | Small-cell Lung Cancer | Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma | Lung Cancer Stage IV | Recurrent Small Cell Lung Carcinoma | Refractory Small Cell Lung Carcinoma | Metastatic Neuroendocrine Carcinoma | Grade I Neuroendocrine Carcinoma | Grade II Neuroendocrine... and other conditions

United States
Case Comprehensive Cancer Center

Recruiting

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Small-cell Lung Cancer | Large Cell Neuroendocrine Carcinoma of the Lung | Extrapulmonary Small Cell Carcinoma

United States
University of Western Ontario, Canada

Completed

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Neuroendocrine Carcinoma (Carcinoid)

Canada
AbbVie

Terminated

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Glioblastoma | Medullary Thyroid Cancer | Malignant Melanoma | Other Solid Tumors | Large-Cell Neuroendocrine Carcinoma | Neuroendocrine Prostate Cancer | High Grade Gastroenteropancreatic Neuroendocrine Carcinoma | Other Neuroendocrine Carcinoma

United States
University of Maryland, Baltimore

Withdrawn

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Small Cell Lung Cancer (SCLC) | Neuroendocrine (NE) Tumors | Large Cell Neuroendocrine (NE) Tumors

United States
Oncology Center of Biochemical Education And Research

Completed

Atezolizumab in Large Cell Neuroendocrine Carcinoma (LANCE)

Large Cell Neuroendocrine Carcinoma of the Lung

Greece
Legend Biotech USA Inc

Recruiting

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage | Large Cell Neuroendocrine Carcinoma of the Lung

United States
Ochsner Health System
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma of the Lung | High Grade Neuroendocrine Carcinoma, Any Site

United States
Technische Universität Dresden
Roche Pharma AG

Recruiting

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE)

Large Cell Neuroendocrine Carcinoma of the Lung

Germany
National Cancer Institute (NCI)

Completed

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Neuroendocrine Carcinoma | Small Cell Carcinoma | Extensive Stage Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Large Cell Lung Carcinoma

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaborators

Completed

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Neuroendocrine Carcinomas

Taiwan
National Cancer Institute, Naples

Completed

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (TENEC)

Neuroendocrine Carcinomas

Italy
University of Turin, Italy

Unknown

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (XELBEVOCT)

Neuroendocrine Carcinomas

Italy
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Rutgers University

Unknown

Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

Carcinoid Neuroendocrine Cancer

United States
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
Shanghai Simnova Biotechnology Co.,Ltd.
Shanghai Chest Hospital

Recruiting

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

China
Barwon Health
Australasian Gastro-Intestinal Trials Group; Deakin University; Specialised Therapeutics...

Unknown

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC)

Gastrointestinal Neuroendocrine Carcinomas

Australia
Rigshospitalet, Denmark

Recruiting

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Non-small Cell Lung Cancer | Malignant Pleural Mesothelioma | Large Cell Neuroendocrine Carcinoma of the Lung

Denmark
Groupe Francais De Pneumo-Cancerologie

Completed

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC)

Large Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)

France
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine Tumors | High Grade Neuroendocrine Carcinoma, Any Site | Well-Differentiated Neuroendocrine Carcinoma

United States
Wren Laboratories LLC

Enrolling by invitation

RegisterNET - A Registry for Neuroendocrine Tumors in the USA (RegisterNET)

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid

United States
Ochsner Health System

Unknown

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid Tumor | Neuroendocrine Cancer | Carcinoid | Islet Cell Tumor | Neuroendocrine | Apudoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditions

United States
Cylene Pharmaceuticals

Completed

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Neuroendocrine Tumors | Carcinoid Tumor

United States
Hospices Civils de Lyon

Active, not recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer (BEVANEC)

Neuroendocrine Carcinomas

France
H. Lee Moffitt Cancer Center and Research Institute

Terminated

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Pancreatic Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinomas of Pancreas | Islet Cell Carcinoma

United States
Phanes Therapeutics

Recruiting

A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)

Small Cell Lung Cancer (SCLC) | Large Cell Neuroendocrine Cancer (LCNEC) | Neuroendocrine Prostate Cancer (NEPC) | Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

United States
Zhejiang University

Completed

Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma

Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditions

United States
Melanoma and Skin Cancer Trials Limited

Recruiting

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

Neuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine Skin

Australia, New Zealand
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
Novartis Pharmaceuticals

Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Adenocarcinoma | Diffuse Large B Cell Lymphoma | Esophageal Adenocarcinoma | Ovarian Adenocarcinoma | Castration Resistant Prostate Adenocarcinoma | Advanced Well-differentiated Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
National Cancer Institute (NCI)

Recruiting

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

SCLC | Advanced Solid Tumor | Small Cell Cancer | High Grade Neuroendocrine Cancers

United States
National Cancer Institute (NCI)

Completed

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Stage III Lung Adenocarcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Gastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States

Clinical Trials on Large-Cell Neuroendocrine Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations